TARGETED siRNA DELIVERY AS AN ANTI-HIV MICROBICIDE
TARGETED siRNA DELIVERY AS AN ANTI-HIV MICROBICIDE
批准号:
7893489
负责人:
Derek Michael Dykxhoorn
金额:
$18.95万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-05-15 至 2012-04-30
关键词:
Anti-Retroviral AgentsAntibodiesBiological ModelsCD4 Positive T LymphocytesCell LineCell physiologyCellsClinicalComplementCytoplasmDendritic CellsDependencyDevelopmentDiseaseDrug Delivery SystemsEnsureEventExploratory/Developmental Grants Phase IIGene SilencingGene Silencing PathwayGene TargetingGenesGenetic MaterialsGenomeHIVHIV Long Terminal RepeatHIV vaccineHIV-1HeterogeneityHeterosexualsImmune systemImmunityIndividualInfectionInfection preventionIntegration Host FactorsIntegrinsLeftLife Cycle StagesLipidsLiposomesLymphocyteMammalian CellMediatingMethodsMucous MembraneMutateOpportunistic InfectionsPhasePreventionProcessProductionProteinsRNA InterferenceReagentResearchSafetySatellite VirusesScreening procedureSexual TransmissionSmall Interfering RNASmall RNAStagingStructureSubfamily lentivirinaeSurfaceSystemT-LymphocyteTestingTherapeuticTopical applicationVaccinesVaginaViralViral GenomeVirionVirusVirus DiseasesVirus IntegrationVirus Replicationbasecell typeclinical applicationefficacy testinggene functiongene therapyin vitro testingin vivointerestmacrophagemicrobicidemouse modelnanoparticlenovelnovel therapeuticspathogenpre-clinicalpreventresearch studytherapeutic genetherapeutic targettissue culturetooltransmission processuptakeviral RNA
中文摘要
描述(由申请人提供):人类免疫缺陷病毒(HIV)是一种高度致命的慢病毒,它会长期破坏宿主的适应性免疫系统,使宿主容易受到许多机会性感染。与大多数基因组独立于宿主细胞基因组复制的病毒不同,HIV-1基因组整合到宿主遗传物质中并与宿主遗传物质一起复制。因此,即使治疗方法可以抑制新病毒的产生,病毒基因组仍然保持完整和有效。因此,能够防止病毒吸收和整合的策略将具有巨大的临床价值。绝大多数HIV感染是由于病毒通过粘膜表面(如阴道粘膜)传播而发生的。将特异性沉默HIV生命周期早期事件所需宿主因子的sirna递送到阴道粘膜淋巴细胞,可能被证明是保护个体免受HIV感染的有效手段,并可作为潜在的杀微生物剂。sirna作为一种遗传疗法的临床应用面临的主要挑战之一是将sirna递送到适当靶细胞类型的细胞质中的能力。我们最近开发了一种新的脂质纳米颗粒,它被一种抗体包裹,这种抗体可以识别在淋巴细胞上广泛表达的整合素分子LFA-1。这些免疫纳米颗粒将被用于将sirna传递到HIV人源化小鼠阴道粘膜中的淋巴细胞。鉴于高水平的序列异质性、HIV-1的突变倾向以及抗HIV sirna无法靶向传入的病毒RNA基因组并阻止整合,需要其他治疗靶点来防止HIV的传播。宿主因子对HIV生命周期的早期事件是必需的,但对细胞功能是必不可少的,可能被证明是一种有效的治疗选择。使用基于高通量RNA干扰的筛选平台,我们已经确定了大量潜在的治疗靶点,这些靶点可以在沉默时抑制HIV整合。然而,这些因素需要广泛的分析和表征,以确保其安全性和有效性。我们将结合lfa -1介导的细胞型特异性载体,引入靶向治疗相关宿主因子的sirna,作为抑制人源化HIV小鼠模型病毒感染的潜在手段。这些实验将为开发一种有效的基于rnai的抗hiv杀菌剂提供必要的临床前基础。异性传播是世界上新发艾滋病毒感染的主要原因。提供真正细胞内免疫的杀微生物剂将对控制这种致命病毒的传播作出重大贡献。
英文摘要
DESCRIPTION (provided by applicant): Human immunodeficiency virus (HIV) is a highly lethal lentivirus which over a protracted course destroys the host's adaptive immune system leaving them vulnerable to numerous opportunistic infections. Unlike most viruses whose genome replicates independently of the host cell's genome, the HIV-1 genome integrates into and is replicated with the host genetic material. Therefore, even if therapeutic approaches can inhibit new virus production, the viral genome remains intact and competent. Therefore, strategies that can prevent the uptake and integration of the virus would be of tremendous clinical value. The vast majority of HIV infections occur as a consequence of viral transmission through mucosal surfaces, such as the vaginal mucosa. The delivery of siRNAs that specifically silence host factors required for early events in the HIV life cycle to lymphocytes in the vaginal mucosa could prove to be an effective means of protecting individuals from HIV infection and serve as a potential microbicide. One of the main challenges facing the clinical application of siRNAs as a genetic therapy is the ability to delivery siRNAs to the cytoplasm of the appropriate target cell types. We have recently developed a novel lipid nanoparticle that is coated with an antibody recognizing the integrin molecule LFA-1 which is broadly expressed on lymphocytes. These immuno-nanoparticles will be used to deliver siRNAs to lymphocytes present in the vaginal mucosa of humanized mouse models of HIV. Given the high level of sequence heterogeneity, the propensity of HIV-1 to mutate and the inability of anti-HIV siRNAs to target the incoming viral RNA genome and prevent integration, alternative therapeutic targets are required to prevent the transmission of HIV. Host factors that are necessary for early events in the HIV lifecycle but are dispensable for cellular functioning could prove to be an effective therapeutic alternative. Using a high-throughput RNA interference-based screening platform, we have identified a large number of potential therapeutic targets that could serve to inhibit HIV integration when silenced. However, these factors require extensive analysis and characterization to ensure their safety and efficacy. We will be combining the LFA-1-mediated cell-type specific vehicle to introduce siRNAs targeting therapeutically relevant host factors as a potential means to inhibit viral infection in humanized mouse models of HIV. These experiments will provide the preclinical groundwork necessary for the development of an effective RNAi-based anti-HIV microbicide. Heterosexual transmission is the leading cause of new HIV infections in the world. A microbicide providing true intracellular immunity would make a significant contribution to controlling the spread of this deadly virus.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Polyunsaturated fatty acids as anti-arrhythmic agents.
-
批准号:10483411
-
项目类别:
-
资助金额:$11.29万
-
财政年份:2022
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Polyunsaturated fatty acids as anti-arrhythmic agents.
-
批准号:10874097
-
项目类别:
-
资助金额:$5.8万
-
财政年份:2022
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Functional genomic studies in diverse populations to characterize risk loci for Alzheimer Disease
-
批准号:10442439
-
项目类别:
-
资助金额:$138.17万
-
财政年份:2021
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Functional genomic studies in diverse populations to characterize risk loci for Alzheimer Disease
-
批准号:10217547
-
项目类别:
-
资助金额:$141.01万
-
财政年份:2021
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Functional genomic studies in diverse populations to characterize risk loci for Alzheimer Disease
-
批准号:10681312
-
项目类别:
-
资助金额:$138.09万
-
财政年份:2021
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Polyunsaturated fatty acids as anti-arrhythmic agents.
-
批准号:10369727
-
项目类别:
-
资助金额:$60.73万
-
财政年份:2016
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Polyunsaturated fatty acids as anti-arrhythmic agents.
-
批准号:10755511
-
项目类别:
-
资助金额:$11.79万
-
财政年份:2016
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Polyunsaturated fatty acids as anti-arrhythmic agents.
-
批准号:10210907
-
项目类别:
-
资助金额:$64.4万
-
财政年份:2016
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Polyunsaturated fatty acids as anti-arrhythmic agents.
-
批准号:10836101
-
项目类别:
-
资助金额:$6.25万
-
财政年份:2016
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
TARGETED siRNA DELIVERY AS AN ANTI-HIV MICROBICIDE
-
批准号:8071962
-
项目类别:
-
资助金额:$17.63万
-
财政年份:2010
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
TARGETED siRNA DELIVERY AS AN ANTI-HIV MICROBICIDE
-
批准号:8880097
-
项目类别:
-
资助金额:$40.63万
-
财政年份:2010
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
TARGETED siRNA DELIVERY AS AN ANTI-HIV MICROBICIDE
-
批准号:8708746
-
项目类别:
-
资助金额:$40.54万
-
财政年份:2010
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
TARGETED siRNA DELIVERY AS AN ANTI-HIV MICROBICIDE
-
批准号:8650542
-
项目类别:
-
资助金额:$38.52万
-
财政年份:2010
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Disease Modeling Core
-
批准号:8740573
-
项目类别:
-
资助金额:$27.92万
-
财政年份:--
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Disease Modeling Core
-
批准号:8268810
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Disease Modeling Core
-
批准号:8932825
-
项目类别:
-
资助金额:$26.83万
-
财政年份:--
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Disease Modeling Core
-
批准号:8539103
-
项目类别:
-
资助金额:$13.31万
-
财政年份:--
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Disease Modeling Core
-
批准号:8379528
-
项目类别:
-
资助金额:$8.43万
-
财政年份:--
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
海外基金